COVID-19 vaccines target emerging variants, offering improved protection. Learn about their effectiveness, timing, and safety ...
Norovirus infection rates are extremely high this year, raising the question: Why can’t a vaccine protect us from the stomach ...
RESVIA® is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) ...
Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.
Moderna has reported revenue of $1bn for the fourth quarter (Q4) of 2024 - a sharp decline from the $2.8bn recorded in the ...
A government advisory committee has canceled a meeting on flu shot recommendations, raising concerns amid shifts in ...
Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...
For now, Moderna may be a good stock to put on a watch list, but it's likely too risky and volatile for the vast majority of ...